Cardiovascular Medicines · LP-044
Acetylsalicylic acid Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-044Cardiovascular Medicines
- Generic identity
- Acetylsalicylic acidTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-044
- Generic identity
- Acetylsalicylic acid
- Presentation
- Tablet
- Catalogue strength
- 81 mg; 100 mg; 250 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Acetylsalicylic acid.
- Dosage form: tablet.
- Catalogue strength / concentration: 81 mg; 100 mg; 250 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Cardiovascular Medicines.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Release/coating character, score/divisibility and excipient composition for 81 mg, 100 mg and 250 mg variants; whether one common blister description is a controlled SKU for all strengths.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
External references show that aspirin strength and release/coating context matter. They do not assign a clinical role or release type to any LP-044 strength.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 81 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer low-dose antiplatelet indication, enteric/delayed release, coating or interchangeability from strength alone. |
| B | 100 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer low-dose antiplatelet indication, enteric/delayed release, coating or interchangeability from strength alone. |
| C | 250 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer low-dose antiplatelet indication, enteric/delayed release, coating or interchangeability from strength alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Acetylsalicylic acid, commonly called aspirin, has antiplatelet, analgesic and anti-inflammatory effects that are used differently in clinical practice. A strength shown in a catalogue does not establish whether a particular tablet is intended for cardiovascular prevention or symptom relief. This distinction matters for safety and labeling. The information here is educational and does not constitute a Luang Pharma approved cardiovascular indication or recommendation to start aspirin.
Clinical context and therapeutic role
For prevention of vascular events, clinicians weigh a person’s established disease and clotting risk against bleeding risk. Aspirin is not appropriate for routine self-directed prevention in everyone. Pain or fever treatment is a separate context with separate eligibility considerations. A medication review should identify other antiplatelets, anticoagulants and anti-inflammatory drugs, and address ulcer history, asthma and upcoming procedures. The actual tablet type and authorized use need confirmation.
Selected safety context
Gastrointestinal bleeding, ulcers and other bleeding are major risks. Aspirin may trigger bronchospasm or serious allergy in susceptible patients. Children and adolescents have specific restrictions because of the association with Reye’s syndrome in certain settings. Kidney disease, pregnancy and concomitant anticoagulants need professional review. Black stools, vomiting blood, unusual prolonged bleeding or breathing difficulty requires urgent care. A patient taking prescribed antiplatelet therapy should seek advice before stopping it for a procedure.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified clinician should review the cardiovascular indication, blood pressure or pulse where relevant, organ function and interacting medicines. Monitoring and treatment changes must be linked to the individual care plan and the authorized product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: AspirinArchived source classification: Public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Aspirin 81 mg delayed-release tablet exampleArchived source classification: US official OTC label example | Source revision recorded: Label updated 15 June 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-044.
Professional enquiries
Request product-specific evidence for LP-044.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.